Fosun Pharma (02196) subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., has signed a "Cooperation and Licensing Agreement" with Sandoz AG.

Zhtng Cijng APP News, Fxng Yyo (02196) issued an announcement recently that its subsidiary company, F Hng Hnln, has signed a "Cooperation and License Agreement" with Sandoz AG. F Hng Hnln grants Sandoz AG the rights to develop, manufacture, and commercialize its investigational product HLX13 (a recombinant anti-CTLA-4 fully human monoclonal antibody injection) in the licensed territories (including the United States, specified European regions <42 European countries>, Japan, Australia, and Canada) and licensed indications (indications approved for marketing in each country within the licensed territories for the specified reference preparations).